Patent · US Active

Kit, composition, and combination therapy for fragile X syndrome

US11590093B2 · kind B2 · utility

0Cited by
2References
11Claims
0Family size

Assignee

Inventor

Key dates

Filing dateApr 12, 2019
Grant dateFeb 28, 2023
Priority date
Expiry dateApr 12, 2039

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P25/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Described herein are kits, compositions, and combination therapies comprising sulindac for use in the treatment of fragile X syndrome (FXS).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.